End-of-day quote
Taipei Exchange
06:00:00 2024-06-06 pm EDT
|
5-day change
|
1st Jan Change
|
73.2
TWD
|
-7.11%
|
|
+0.41%
|
+8.12%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
530.2
|
965.7
|
4,753
|
5,659
|
7,326
|
4,798
|
Enterprise Value (EV)
1 |
407.2
|
678.1
|
4,418
|
4,177
|
5,942
|
3,532
|
P/E ratio
|
-7.12
x
|
-12.6
x
|
-55.5
x
|
-53.2
x
|
-51.9
x
|
-27.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
10,288,798,701
x
|
908,447,183
x
|
22,335,548,780
x
|
-
|
EV / Revenue
|
-
|
-
|
9,563,748,918
x
|
670,590,705
x
|
18,117,189,024
x
|
-
|
EV / EBITDA
|
-6.87
x
|
-11.3
x
|
-68.6
x
|
-56.5
x
|
-46.3
x
|
-21.6
x
|
EV / FCF
|
-13.8
x
|
3.42
x
|
-16.7
x
|
-122
x
|
-115
x
|
-49.1
x
|
FCF Yield
|
-7.27%
|
29.3%
|
-5.99%
|
-0.82%
|
-0.87%
|
-2.04%
|
Price to Book
|
2.21
x
|
5.72
x
|
11
x
|
3.61
x
|
5.02
x
|
3.64
x
|
Nbr of stocks (in thousands)
|
38,170
|
38,320
|
51,950
|
69,009
|
69,772
|
70,871
|
Reference price
2 |
13.89
|
25.20
|
91.50
|
82.00
|
105.0
|
67.70
|
Announcement Date
|
4/3/19
|
3/30/20
|
3/26/21
|
3/21/22
|
3/22/23
|
3/19/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
0.462
|
6.229
|
0.328
|
-
|
EBITDA
1 |
-59.31
|
-59.88
|
-64.41
|
-73.88
|
-128.3
|
-163.6
|
EBIT
1 |
-75.9
|
-76.84
|
-84.11
|
-94.42
|
-148.4
|
-186.3
|
Operating Margin
|
-
|
-
|
-18,204.76%
|
-1,515.81%
|
-45,252.44%
|
-
|
Earnings before Tax (EBT)
1 |
-74.47
|
-76.22
|
-82.01
|
-91.58
|
-140.2
|
-170.9
|
Net income
1 |
-74.47
|
-76.22
|
-82.01
|
-91.58
|
-140.2
|
-170.9
|
Net margin
|
-
|
-
|
-17,751.3%
|
-1,470.14%
|
-42,737.8%
|
-
|
EPS
2 |
-1.951
|
-1.993
|
-1.650
|
-1.540
|
-2.023
|
-2.430
|
Free Cash Flow
1 |
-29.58
|
198.4
|
-264.7
|
-34.31
|
-51.5
|
-71.93
|
FCF margin
|
-
|
-
|
-57,288.64%
|
-550.85%
|
-15,701.03%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/3/19
|
3/30/20
|
3/26/21
|
3/21/22
|
3/22/23
|
3/19/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
123
|
288
|
335
|
1,482
|
1,384
|
1,266
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-29.6
|
198
|
-265
|
-34.3
|
-51.5
|
-71.9
|
ROE (net income / shareholders' equity)
|
-26.9%
|
-37.3%
|
-27.1%
|
-9.14%
|
-9.26%
|
-12.3%
|
ROA (Net income/ Total Assets)
|
-16.5%
|
-14.3%
|
-12%
|
-5.79%
|
-6.04%
|
-8.17%
|
Assets
1 |
451.2
|
534.1
|
681.7
|
1,581
|
2,321
|
2,093
|
Book Value Per Share
2 |
6.290
|
4.400
|
8.330
|
22.70
|
20.90
|
18.60
|
Cash Flow per Share
2 |
1.090
|
6.590
|
0.9000
|
7.990
|
3.540
|
2.340
|
Capex
1 |
0.45
|
5.28
|
1.8
|
2.18
|
5.23
|
7.21
|
Capex / Sales
|
-
|
-
|
389.39%
|
35.03%
|
1,592.99%
|
-
|
Announcement Date
|
4/3/19
|
3/30/20
|
3/26/21
|
3/21/22
|
3/22/23
|
3/19/24
|
|
1st Jan change
|
Capi.
|
---|
| +8.12% | 161M | | +51.85% | 57.87B | | +41.42% | 40.25B | | -5.25% | 39.94B | | -5.16% | 28.54B | | +12.79% | 26.4B | | -20.18% | 19.33B | | +30.88% | 12.4B | | +0.61% | 12.23B | | +25.06% | 12.2B |
Other Biotechnology & Medical Research
|